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Introduction
The data presented here are gathered from across all
transplant procedures to provide an overview of the
state of transplantation among children. The analyses
that follow are intended to provide clarity within each
area of review regarding patients aged 17 and under,
from waiting list registration through 5-year survival of
patients and grafts. While it is difficult to draw overall
conclusions from a decade’s worth of data for six different
transplant procedures, a few developments can be identified.
Unless otherwise noted, the statistics in this article come
from reference tables in the 2002 OPTN/SRTR Annual
Report. Two companion articles in this report, ‘Data Sources
and Structure’ and ‘Analytical Approaches for Transplant
Research’, explain the methods of the data collection, organ-
ization, and analysis that serve as a basis for this article (1,2).
In 2001, the number of pediatric registrants continued to
increase in all age groups, except among children younger
than 1 year. While the total number of pediatric registrants
more than doubled since 1992, parallel growth in the adult
population of registrants led to a gradual decline in the relative
percentage of pediatric patients among total registrants from
a high of 4% a decade ago, leveling at around 3% since 1999.
From 1992 to 2001, the greatest increase in pediatric regis-
trants awaiting transplant was observed for the intestine and
lung waiting lists, both of which grew approximately fourfold.
Currently, the liver waiting list contains the largest number of
pediatric registrants, with some 1104 children listed at the end
of 2001. Unlike the growth experienced over the decade in
other types of pediatric transplantation, the number of children
awaiting and receiving kidney transplants has been relatively
stable. Given that the incidence of end-stage renal disease
(ESRD) has not increased in children in many years, the prac-
tice of aggressively identifying and transplanting these
patients has kept the number of pediatric kidney transplants
steady over the years.
Living donor grafts played a prominent role over the dec-
ade. Increased availability of these grafts supported a
slight rise in the number of kidney transplants performed
in children. Among pediatric recipients of liver transplants,
increasing numbers of children aged 11–17 years received
living donor grafts.
Pediatric Donor Overview
In 2001, there were 978 deceased pediatric donors. The
absolute number of such donors remained fairly constant
over the last decade (range 963–1213). However, the
percentage of deceased pediatric donors declined from
23% in 1993 to 16% in 2001 because of a significant
increase in adult donors above age 35. It is worth noting
that, as with pediatric donors, the number of deceased
donors aged 18–34 years also remained relatively constant.
The stability of the total number of pediatric donors over
the past decade suggests that initiatives to increase
awareness and bolster consent rates remain worth pursu-
ing (3). Additionally, while strides were made over the last
decade in accepting more expanded criteria adult donors,
it is uncertain to what extent such donors are present in
the pediatric population. Finally, it remains to be determined
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how growth in the use of nonheartbeating donors will affect
the total number of pediatric donors relative to adult donors.
Figure1 summarizes the contribution of deceased pediatric
donors by organ. In 2001, pediatric donors constituted 16%
of all deceased kidney donors, with the majority of pediatric
kidney donors (n¼ 496) aged 11–17years. Nearly all pediatric
deceased donors were kidney donors, except for those less
than1yearofage,ofwhomonly48%donatedkidneys in2001.
Overall, pediatric donors were most likely to be kidney donors
(92%), then liver donors (86%), and heart donors (49%).
Analysis of pediatric organ donation on the basis of age
subgroups revealed that pediatric pancreas and lung
donors tended to be older children, while intestine donors
were more likely to be aged 5 and younger (Figure 2). Liver
and heart donors exhibited roughly even distribution
across age groups. Overall, pediatric donors were much
more likely to be pancreas, intestine, or heart donors
than their adult counterparts; for kidney, liver, and lung
donation, contributions between the two groups were
relatively well matched (Figure 3).
Kidney Transplantation
Waiting list
Over the past four decades, kidney transplantation has
become a highly successful treatment for children with
ESRD, and the transplant community has come to recog-
nize that indications, endpoints, procedures, complications,
pharmacokinetics, and outcomes are different for children
than they are for adults. In response to these differences,
dedicated pediatric registries, such as the North American
Pediatric Renal Transplant Cooperative Study were devel-
oped to address the special requirements of children (4).
Nonetheless, a comprehensive database such as the SRTR
is essential for defining the comparative outcomes of
children and adults—and for identifying opportunities to
improve the outcomes of both groups.
In 2001, pediatric patients represented 1.4% of all regis-
trants on the kidney waiting list. Although the number of
pediatric patients awaiting renal transplantation continued
to increase, the relative percentage of pediatric patients
represented on the waiting list declined over the decade
from 3% of all registrants in 1992. This decrease reflects
the explosive growth in the number of adult registrants.
Of pediatric patients listed for cadaveric renal trans-
plantation in 2001, 69% were aged 11–17 years. Only
1–3 children younger than 1 year were on the waiting list
at each year-end snapshot. The relative distribution by age
groups remained relatively stable over the decade.
For pediatric waiting list registrations, the median time to
transplant was significantly shorter than for adults. For
children aged 1–5 years and 6–10 years, the median time
to transplant decreased somewhat in the past 3 years, albeit
not drastically. Over the last 10 years, median time to trans-
plant has remained relatively constant or even decreased
slightly in all pediatric age groups, unlike the adult age
groups, where time to transplant has increased relentlessly.
Annual death rates among pediatric registrants awaiting






















Figure 1: Deceased donors by organ, adult vs. pediatric, 2001.








































Figure 2: Deceased pediatric donors by organ and age group, 2001.

































Figure 3: Percent donation of organs of adult and pediatric
deceased donors, 2001. Source: 2002 OPTN/SRTR Annual
Report, Tables 2.1–2.7.
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overall since 1992. Of all registrants on the kidney waiting
list, children aged 6–17 had a significantly lower death
rate. In contrast, children aged 1–5 demonstrated a sig-
nificantly higher mortality rate, approaching that observed
for older adults (i.e. those aged 35–49 and older).
Without question, renal transplantation is the standard of
care for children with ESRD. Unfortunately, a significant
shortage of donor organs contributes to waiting list mor-
bidity and mortality. This situation exists despite the virtual
absence of donor size limitations that are important to
most extrarenal transplants in children. Continued growth
of living donor renal transplantation will help continue to
relieve pressure on the waiting list.
Waiting list: pancreas and kidney–pancreas
Currently, pediatric patients are rarely listed for pancreas
transplant, and even less frequently for kidney–pancreas.
Because there are so few pediatric patients, meaningful
analysis of wait time or mortality awaiting transplant is not
feasible.
Transplantation and survival
In the past, young kidney recipients have generally been
considered at higher risk, showing diminished graft sur-
vival compared with older children and adults (4,5). In many
reports, the worst survival rates were seen in the young-
est patients, and speculation concerning the causes of
these poor results centered around the hypothesis of
heightened immune responsiveness in very young
children (5). Improvements in surgical technique, donor
selection, and immunosuppression practices, as well as
the enhanced experience of specialized pediatric trans-
plant teams, have all led to marked improvements in
patient and kidney graft survival for infants and young
children (6,7). Indeed, recent analyses have identified
these patients as now having the best long-term survivals
of all age groups (8,9). Young recipients of adult-sized
kidneys who have immediate graft function have been
reported as having the longest projected graft half-lives,
exceeding even those of adult recipients of 2-haplotype
matched living donor transplants (10). Adolescent kidney
recipients have now replaced infants as having
comparatively poor outcomes. The reasons for the
increased graft failure in adolescents remain speculative.
The incidence of ESRD in children increased only slightly
during the past decade, and this is reflected in the waiting
list for kidney transplants. At the end of 1992, 630 children
younger than 18 years were on the waiting list for kidney
transplants; by the end of 2001 there were 701, an
increase of only 11%. In contrast, the number of adults
on the list more than doubled, from 21 433 to 50 443.
Importantly, the increases were not seen uniformly
throughout the adult age groups. While the number of
registrants aged 18–34 increased by 34% in that time
frame, those aged 50–64 years increased more than
threefold and those over 65 almost sixfold. It would
appear the waiting list is indeed aging. Thus, the percent-
age of those on the list who were children decreased from
3% to 1% over the past decade.
The OPTN has always given preference to children await-
ing cadaveric renal transplant. Initially, children were pre-
ferentially allocated kidneys from deceased donors less
than 10 years old. Unfortunately, these donors turned out
to be high-risk, and the combination of high-risk donors for
high-risk recipients resulted in very poor outcomes for
pediatric recipients of cadaveric kidneys (11,12). The
allocation system was subsequently changed, first by
additional points and then to the present system of placing
pediatric patients at the top of the waiting list after waiting
times between 6 and 18 months (depending on recipient
age). These newer systems unquestionably contributed to
improvement in graft outcomes for children and main-
tained relatively short waiting times. For example, the
median waiting time for those aged 1–5 years at listing
was 212 days in 1992 and 205 days in 2001. The waiting
times for registrants in other pediatric age groups
remained comparably low, while the waiting times of
adults increased by a factor of more than two.
The number of children who received kidney transplants
increased slightly over the past decade, almost entirely
attributable to an increased number of living donor trans-
plants. Of the 592 pediatric kidney transplants performed in
1992, 315 were from living donors, rising to 434 of 723 in
2001. Thus, living donors currently account for 60% of kid-
ney transplants for children. Children were the recipients of
4% of all kidney transplants from deceased donors, and 7%
from living donors. Interestingly, in 2001, 898 adults over
age 65 received kidneys from deceased donors. Thus, three
times as many kidneys were allocated to those over age 65
than to those less than 18, once again emphasizing the
aging of the kidney waiting list.
Mortality for children on the waiting list was very low.
Only nine children died while awaiting kidney transplant-
ation last year. The lowest mortality was among those aged
6–10 years. Mortality among those younger than 6 was as
high as that of patients aged 35–49 years. Previous studies
have demonstrated that mortality in children aged
1–5 years receiving dialysis is three times higher than for
those who receive transplants (6,13,14). The reasons for
this unacceptably high mortality are not known, and this
area obviously deserves more careful study.
Graft survival rates for pediatric kidney recipients
improved substantially during the past decade and now
rank among the most successful of all transplants. This
outcome may seem surprising given children’s poor
outcomes previously. Pediatric recipients under age 11
who received living donor kidney transplants had 5-year
graft survival rates that were as good or better than most
older age groups (92% for those younger than 1 year, 81%
for those aged 1–5 years, and 80% for those aged
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6–10 years) (Figure 4). The results of cadaveric kidney
transplants were also slightly better than those seen in
adults, with recipients aged 1–5 years having a 5-year graft
survival rate of 68% and those aged 6–10 years having the
best graft survival rate of all age groups at 72%. These
outcomes are consistent with recent reports showing that
the longest half-lives of all recipients are in the youngest
patients, especially the pediatric recipients of adult-sized
grafts who have immediate graft function (8,10). Unfor-
tunately, these excellent results in young children were
not seen in adolescent recipients. The 5-year graft survival
rate of recipients aged 11–17 years who received living
donor transplants was 73%, which is roughly equivalent
to the results of adult recipients. The adolescent recipients
of cadaveric grafts had a 5-year graft survival rate of 54%.
This was worse than rates for all other pediatric and adult
age groups except for those aged 65 years and older. The
reasons for the poor long-term outcome for the teenage
group are unknown, but noncompliance with immunosup-
pressive medications may play a part. Of course, other
causes are also possible, including an unexplained high
frequency of graft thrombosis (15) and the high incidence
of recurrence of focal segmental glomerulosclerosis (16),
which is the most common acquired cause of ESRD in this
age group. More recent (1999–2000) recipients of cadave-
ric grafts in this age group generally had excellent
short-term (3-month and 1-year) graft survival rates. Since
first-year death rates for 1999–2000 are lower than those
for 1995–96 (the cohort of patients for whom 5-year graft
and patient survival is reported), it is possible that the
longer-term outcomes for this more recent cohort of patients
will be better. Until the causes of the diminished graft sur-
vival are known, special attention should be paid to this newly
identified high-risk teenage group, and using living donors for
their kidney transplants should be given strong consideration.
As expected, first-year death rates of pediatric kidney
transplant recipients were generally lower than those of
adults and 5-year patient survival rates were higher.
The 5-year patient survival rates for children 1–5, 6–10,
and 11–17 years old were 93%, 93% and 95%, respec-
tively. The youngest recipients, however, may have a
slightly higher first-year death rate than older children
and young adults. There were 2 deaths in 228 patients
1–5 years old, resulting in a rate of 18 deaths per 1000
patient years at risk—two to three times higher than
older children and young adults. Since the numbers are
so small for this age group, however, the significance of
the finding is not clear. And, even if the finding is true, it
may be difficult to define a cause of the elevated mortality
rate.
The use of children as kidney donors has not been well
studied. The number of pediatric deceased donors has
remained stable over the decade. In 1992, there were
1008 deceased kidney donors under age 18 and in 2001
there were 978. Those numbers represented 22% and
16%, respectively, of all deceased donors in those years.
The current percentage of pediatric deceased donors of
kidneys therefore was substantially greater than the per-
centage of pediatric candidates on the waiting list (1%) or
cadaveric kidney recipients (4%). Kidneys from donors
aged 11–17 years had the best short- and long-term graft
survival rates, with 5-year graft survival at 71%. Grafts
from younger donors, however, are less successful (11).
The 5-year graft survival rate for organs from deceased
donors younger than 5 years was 60%, which is equiva-
lent to that for organs from donors aged 50–64 years
(55%) and superior to those for organs from donors
older than 65 (42%). Thus, those very young donors
might best be described as expanded criteria donors and
the use of their organs for selected recipients should be
encouraged. The use of children for living kidney donation
remains highly controversial and is generally avoided,
except in very limited circumstances, such as identical
twins, or in the case of an emancipated minor for his or
her own child (17,18). In general, most transplant pro-
grams will not accept a living donor younger than
18 years for a kidney transplant.
In summary, over the past decade the picture for graft
survival among pediatric renal transplant recipients
improved markedly. Certain subgroups of children had
the best long-term graft and patient survival rates of all
transplant recipients. This success, however, was not uni-
form among all recipient age groups. Improvements in
donor selection, operative techniques, immunosuppres-
sive protocols, and long-term follow-up are all possible
methods of improving outcomes. Children are generally
transplanted early in the course of ESRD care, since the
majority of these patients receive grafts from living
donors. Those waiting for cadaveric kidneys experience
shorter times to transplant than do adults, since allocation


























Figure 4: Graft survival among recipients of living donor kidney
transplants, by recipient age. Source: 2002 OPTN/SRTR Annual
Report, Table 5.8. Cohorts are for transplants performed during
1999–2000 for 3-month and 1-year; 1997–1998 for 3-year; and
1995–1996 for 5-year survival.
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Liver Transplantation
Waiting list
Over the past decade, the number of children registered
on the waiting list for a liver transplant rose steadily, the
most dramatic example being a fivefold increase among
those aged 11–17. The number of pediatric registrants
rose two- to threefold in the other childhood age groups.
Yet even these increases do not match the staggering rise
in the number of adults on the liver waiting list. Since
1992, the number of registrants aged 50–64 years await-
ing a liver transplant has grown by a factor of 10. As a
result of this huge increase in adults on the waiting list,
the relative percentage of children on the list decreased
from 16% in 1992 to 6% in 2001. Adults aged 50–64 years
now represent 48% of all the registrants waiting for liver
transplantation. Although patients 5 years or younger
receive 6% of all the liver transplants from deceased
donors each year, they represent only 3% of the waiting
list.
It is difficult to compare adult and pediatric patients
by liver status because the diseases accounting for
transplant are different between the populations, and the
status system is not exactly the same for both popula-
tions. This especially affects the relative percentages of
the 2B and 3 categories, which include most of the
patients.
For pediatric registrants, the median time to liver trans-
plant was significantly shorter than for adults. The shortest
median time to transplant was seen among those aged
6–10 years. Despite these findings, time to transplant
generally increased over the last decade for pediatric
registrants. It is encouraging to note, however, that since
1999, the median time to transplant decreased among
those aged 6–17 years. Unfortunately, time to transplant
appears to have increased over the same period for chil-
dren aged 5 years and younger.
Death while waiting for a transplant has decreased for all
pediatric age groups since 1992. These youngest regis-
trants had the highest mortality on the waiting list (572
deaths per 1000 patient years at risk) of any group waiting
for a liver transplant, five times the average for all regis-
trants. Death rates for older children ranged between 40
and 162 per 1000 patient years at risk.
The introduction of living donor liver transplantation and
the re-emergence of split liver transplantation represent
significant advances for pediatric patients (19,20). None-
theless, given the critical shortage of donor organs,
waiting list mortality remains unacceptably high, particu-
larly among children below age 5. The effect of the recent
introduction of the Pediatric End-stage Liver Disease
(PELD) score (21) and other changes in organ allocation
policy will be monitored closely.
Transplantation and survival
Over the last decade, an average of 477 cadaveric liver
transplants were performed yearly in pediatric patients,
with peak activity occurring in 1998 (520 transplants). In
2001, over half of all children transplanted were 5 or
younger, and 26% were 1 or younger.
The proportion of pediatric donor livers that have been
transplanted into pediatric recipients has remained fairly
constant at around 40%. A recent change in allocation
policy for these candidates will direct more pediatric livers
toward children and may affect this proportion in the
future.
Hepatic allograft survival rates in the pediatric age groups
compare favorably with overall allograft survival rates
(76–86% for children vs. 86% overall) at 3 months.
Children younger than 1 year had worse allograft survival
in the early postoperative period, but by 5 years were
similar to the overall rate (62% vs. 64%). As with kidney
transplants, a disturbing trend toward inferior graft survival
among patients aged 11–17 years at 3 and 5 years post-
transplant was notable, when compared to the results for
other children and adults. One-year survival was 83%,
3-year survival was 69%, and 5-year survival was 60% in
the teenage group. Although these results are from differ-
ent cohorts, if the 3- and 5-year results persist for the
most recent cohort then the rate of decline in graft survival
will be steeper for 11–17-year-olds than for most other
age groups.
Patient survival for children after liver transplantation com-
pares favorably with adults, except for children under
1 year at 3 months following a liver transplant. At 5 years
of follow-up, these youngest children survived at a rate
similar to adults (78% vs. a range of 61–77% for the adult
subgroups). Children aged 6–10 years had the best 5-year
survival rate among all patient groups (88%). Patient
survival rates for African Americans were lower than for
recipients of other races at all points of follow-up.
The use of living donor grafts has steadily increased. In
1992, 1% of all liver transplants were from living donors,
compared with 10% in 2001. Until 1999, pediatric patients
constituted most of the recipients of living donor grafts.
Since then, however, a major increase in adult-to-adult
living donor liver transplantation has occurred, reducing
the proportion of living donor transplants accounted for
by children. Thus, 97% of living donor recipients in 1992
were children (younger than 18 years). But by 1999, 39% of
living donor grafts were transplanted into children, and only
21% of the recipients of living donor grafts were children in
2001. Conversely, the percentage of pediatric recipients
who received living donor grafts was only 6% in 1992.
This increased to 14% in 1997, and its peak to date, 19%,
occurred in 2000 as the absolute number of these grafts
increased by three times over the course of the decade.
Pediatric transplantation
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Until 1998, the majority of all living donor liver grafts went
to children under age 1. In 1997, 54% of all living donor
grafts were placed into children in this age range. After
1997, these youngest children still formed the largest
group of pediatric living donor recipients. However, in
1999, increasing numbers of older children (11–17 years)
began to receive living donor grafts. Of pediatric living
donor recipients in 1997, only two of 81 were between
ages 11 and 17, but by 2001, the number rose to 18 of 107
pediatric living donor recipients. This paralleled the
increasing number of adult living donor recipients, three
in 1997 compared with 408 in 2001.
Patient survival for pediatric recipients of cadaveric liver
transplants is shown in Figure 5. In comparison, for the
cohort of patients transplanted in 1999–2000, 1-year
patient survival for pediatric recipients of living donor
grafts ranged from 80% (n¼ 15) for children aged
6–10 years to 100% for children aged 11–17 years (n¼ 17)
(Figure 6). For the majority of children receiving living
donor grafts children less than 1 year (n¼ 85) and children
aged 1–5 years (n¼ 64): 1-year patient survival rates
were 87% and 83%, respectively. These values remained
virtually the same at 3 years, 85% for both, for the cohort
of children receiving transplants between 1997 and 1998.
For the same patient cohorts, 1-year graft survival for
living donor grafts transplanted into children was lowest
for recipients aged 1–5 years (75%) and highest for recip-
ients younger than age 1 (81%). However, concordant
with results for patient survival, by the third year, graft
survival was very similar for all age ranges (77%).
Adequate follow-up for older children is not yet available.
Comparing pediatric with adult recipients of living donor
grafts, 1-year patient survival for children receiving such
grafts was similar to results for adults receiving them. The
lowest 1-year patient survival for adults was in patients
older than 65 (76%); the best 1-year survival was seen in
recipients 35–49 years old (92%). Interestingly, adult
recipients of living donor grafts tended to have lower
1-year graft survival compared with children. The best
survival was reported for recipients aged 35–49 years,
79% for 149 patients; the lowest survival was reported
for recipients older than 65, 69% for 29 patients. Insuffi-
cient numbers preclude calculations of three-year graft
survival values for adult living donor recipients.
Intestine Transplantation
Waiting list
In 2001, 74% of registrants on the intestine waiting list
were 17 years old or younger, and half of these 134
registrants were between ages 1 and 5. Since 1992, the
number of pediatric registrants increased approximately
fourfold.
Because of relatively small numbers, the median time to
transplant is difficult to analyze meaningfully. Despite this
limitation, children younger than 1 at time of registration
had a strikingly higher median time to transplant compared
to other pediatric and adult patients.
Among registrants awaiting intestine transplant, annual
death rates were highest in children under 1 year of age,
followed by those 1–5 year old. Many patients awaiting
intestine transplantation are also awaiting a liver trans-
plant. The current MELD/PELD allocation system may
























Figure 5: Patient survival among pediatric recipients of deceased
donor liver transplants, by recipient age. Source: 2002 OPTN/
SRTR Annual Report, Table 9.9. Cohorts are for transplants
performed during 1999–2000 for 3-month and 1-year; 1997–1998
























Figure 6: Patient survival among pediatric recipients of living
donor liver transplants, by recipient age. Source: 2002 OPTN/
SRTR Annual Report, Table 9.9. Cohorts are for transplants
performed during 1999–2000 for 3-month and 1-year; 1997–1998
for 3-year; and 1995–1996 for 5-year survival.
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with more common etiologies of liver disease, further
contributing to waiting list mortality.
As intestine transplantation continues to mature (22,23), it
is reasonable to expect continued waiting list growth. The
quality of donor organs, along with size considerations and
constraints on cold ischemia times, remain limiting factors.
Transplantation and survival
In 2001, 61 intestinal transplants were performed in
pediatric patients. This number is very small compared
with numbers for other organ transplants, but it repre-
sents a dramatic increase over the 10 intestinal
transplants performed in 1992. In 2001, over half of all
intestinal transplants performed were in children, and
56% of these occurred in children aged 1–5 years.
Patient and graft survival for intestinal transplantation
were 62% and 34%, respectively, at 3 years post-
transplant in the group demonstrating the most transplant
activity (ages 1–5). Patient survival for pediatric recipients
of intestinal transplants by age group is shown in Figure 7.
Heart Transplantation
Waiting list
The number of pediatric registrants listed for heart trans-
plantation has remained relatively stable since the
mid-1990s. Little change was seen in the age distribution
of new heart waiting list registrations, with the preponder-
ance of pediatric heart transplant registrants aged less than
1 year. This reflects the needs of children with complex
congenital heart disease unsuitable for surgical repair or in
need of transplantation after failed surgical intervention.
The number of new registrations decreased in children
aged 6–10 years, reflecting a relatively lower incidence of
cardiomyopathies in this age group. It gradually increased
again in those aged 11–17 years, reflecting the effects of
end-stage cardiomyopathies and congenital heart disease
as an increasing indication for transplantation in this age
group. In 2001, cardiomyopathy accounted for 54% of all
registrants, while congenital heart disease accounted for
40%. Coronary artery disease is vanishingly rare among
pediatric patients, in contrast to adults.
The median time to heart transplant was substantially
lower among pediatric than adult registrants. Since 1999,
the median time to transplant among registrants aged
6–10 decreased. Wide variability in waiting times for
patients younger than 1 year makes analysis in this subset
of patients problematic.
The incidence of death while awaiting heart transplant-
ation was extremely high in registrants under 1 year (1373
waiting list deaths per 1000 patient years at risk). These
infants often have complex congenital heart disease, are
relatively unstable, and are unable to be supported
adequately for longer waiting times. The rate of mortality
among this youngest group was almost 10 times the
overall waiting list mortality for cardiac transplantation
across all age ranges. In children aged 1–5 years, waiting
list mortality was 377 per 1000 patient years at risk, more
than twice the overall mortality for all registrants, and in
those aged 6–10 years the rate of death while waiting was
similar to the overall waiting list mortality.
The waiting list death rate was high in registrants aged
11–17 years (279 per 1000 patient years), twice the wait-
ing list death rate for older registrants. The increased rate
of death while waiting may reflect the severity of con-
genital heart disease and cardiomyopathy occurring in
children and possibly the need for more accurate size
matching, which may result in slightly fewer potential
donors for these recipients. The median time to transplant
is actually slightly lower for pediatric registrants than for
adults. However, the increased waiting list mortality may
reflect the instability of the patients and the relatively
fewer potential donors for these smaller recipients.
Continued growth in the number of pediatric patients
awaiting heart transplantation is likely. The shortage of
smaller organs, along with a lack of alternative mechanical
support devices for children, contributes to mortality in
pediatric patients awaiting transplantation.
Transplantation and survival
Pediatric cardiac transplantation has been stable in volume
since the early 1990s. Approximately 12% of all cardiac
transplants were performed in patients younger than age
18, a proportion that was constant over the last 5 years.
There has been a trend over the last decade for more
pediatric donor hearts to be transplanted into pediatric
























Figure 7: Patient survival among pediatric recipients of deceased
donor intestine transplants, by recipient age. Source: 2002 OPTN/
SRTR Annual Report, Table 10.9. Cohorts are for transplants
performed during 1999–2000 for 3-month and 1-year; 1997–1998
for 3-year; and 1995–1996 for 5-year survival.
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most recent part of this increase may have resulted in part
from an allocation policy change (Policy 3.7.5), which
states that within each heart status category, pediatric
donor hearts are allocated preferentially to pediatric
recipients.
The number of pediatric heart transplant recipients under
1 year of age has slightly decreased over the past 4 years.
In 2001, 64 patients received a transplant at or below
1 year, down from 95 in 1997 and a high of 107 in 1993.
The number of recipients aged 1–5 years increased slightly
to a decade high of 82 in 2001, possibly reflecting
increased activity in transplantation for congenital heart
disease that has not improved with surgical reconstruction
or palliation. The number of recipients aged 6–10 years
decreased from 47 in 2000–28 in 2001, the lowest number
since 1992. The number of recipients aged 11–17 years
has remained relatively constant during the past 5 years at
approximately 80–100 patients per year.
Graft survival rates for pediatric heart transplant recipients
show a higher early mortality for patients under 1 year;
3-month survival for this group was 86% compared with
survival rates of 88% or better in all other age groups. This
lower survival likely represents the complexity of trans-
plantation in the first year of life in children with complex
congenital heart disease. Surgical reconstruction can fail in
these youngest patients, and these infants have often
waited a significant time for donor organ availability with
unprotected pulmonary blood flow and the consequent
development of elevated pulmonary vascular resistance.
In spite of the decreased 3-month survival in these young-
est recipients, 72% patient survival at 5 years (in a
separate cohort) was actually somewhat higher than the
other pediatric age groups. Thus, despite higher early
postoperative mortality, late mortality appears to be
lower, consistent with the possible immune advantage
noted in young infants who undergo cardiac transplant-
ation. Therefore, the long-term improved survival may
reflect better graft acceptance with effective immuno-
suppression in this subgroup of patients. After the first
year of age, there appears to be no significant difference
in outcome at 5 years compared to other age groups.
Early graft survival continued to be slightly lower in
recipients aged 1–5 years (88%) compared with older
children, possibly suggesting again more difficult cardiac
anatomy with failed reconstruction for complex congenital
heart disease or severe cardiomyopathy at this early age.
Data on graft survival also show that survival after a sec-
ond transplant is worse than initial transplant survival.
Although 3-month survival does not appear significantly
different at 84% vs. 89%, at 5 years the retransplant
population has a 49% survival compared to 69% in the
first transplant group.
Younger donor age (under 18 years) is associated with
graft survival rates ranging from 85% to 92% at 3 months
and with rates ranging from 63% to 74% at 5 years. These
survival rates are slightly better than survival rates with
older donor ages and represent the relative advantage of
young donor grafts with less risk of coronary disease or
other cardiac abnormalities. In keeping with these obser-
vations, current OPTN heart allocation policies preferen-
tially direct pediatric organs to pediatric recipients.
Patient survival correlates with graft survival, with slightly
lower patient survival in the very youngest recipients at
3 months (Figure 8). At 5 years, survival in this group was
higher than several of the older age groups.
Data for the 2001 pediatric heart transplantation population
continue to suggest stability in both donor availability and
the number of new patients listed yearly. A slight increase
in patient registrations occurred among those aged 1–5
years. This suggests that cardiac transplantation is used
more frequently as a salvage therapy for patients in whom
staged reconstruction for a single ventricle was unsuccess-
ful or who have other complex cardiac malformations.
Recent interest has developed in the use of non-ABO
matched donors for infant and pediatric cardiac transplant-
ation (24). The effect of the use of ABO mismatched donors
on overall graft availability and survival rates is yet to be
determined. It is apparent, however, that when the number
of new registrants aged under 1 year (178 in 2001) is com-
pared with the number of transplants performed (64 in
2001), organ availability is a significant problem. Data are
not available to ascertain the total number of potential infant
donor hearts not utilized, since some potential infant donors
may not have had any organs procured for transplant in the
absence of suitable recipients. However, among 84 donors
less than 1 year of age from whom at least one organ was
procured, only 59 hearts were procured and transplanted. If
























Figure 8: Patient survival among pediatric recipients of deceased
donor heart transplants, by recipient age. Source: 2002 OPTN/
SRTR Annual Report, Table 11.9. Cohorts are for transplants
performed during 1999–2000 for 3-month and 1-year; 1997–1998
for 3-year; and 1995–1996 for 5-year survival.
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recipients, then ABO mismatching could improve overall
transplantation rates and potentially affect survival rates
among those awaiting transplant. Any post-transplant effect
on patient and graft survival rates at 3 months and 5 years,
however, would remain to be determined.
Lung Transplantation
Waiting list
Pediatric lung transplantation continues to be an infre-
quent procedure. New pediatric waiting list registrations
for lung transplant peaked in 1998 at 152 and decreased to
109 and 115 in 2000 and 2001, respectively. In children
under age 1, only nine new registrations were noted in
2001, with a similar number in those aged 1–5 years. The
number of registrants aged 6–10 years also decreased (18
in 2001 vs. 22 in 2000 and 30 in 1999). This pattern also
occurred among those registrants aged 11–17 years, an
age group in which cystic fibrosis is a common indication
for transplantation. New registrations peaked in 1998 in
this group. The causes for decreased registrations for lung
transplants in the pediatric population is unclear. However,
improved management of cystic fibrosis, which allows
patients to achieve older ages before listing for transplant,
may account for some of the decrease. In addition, the
contribution of living donor lobar transplantation in the
pediatric population with cystic fibrosis must be also
considered. The number of lung lobe donors peaked in
1999 at 56, then decreased in 2000 to 30 and in 2001 to
37. The majority of donors were 35–49 years old (25).
Analyses of median waiting times to lung transplant are
inconclusive because of the insufficient number of
patients followed and the small number of waiting list
registrations in younger children. No data on waiting time
is noted in patients under age 11. Among those aged
11–17 years, the largest group of pediatric lung transplant
registrants, median waiting times are not yet known for
2001 registrants. However, the 10th percentile of time to
transplant was 200 days, similar to both 2000 and 1999.
These waiting times appear to be slightly longer than the
10th percentile of time to transplant in patients aged
18–34 years and in the older age ranges, suggesting that
adolescent recipients appeared to be waiting slightly
longer than their adult counterparts for donor organs.
The overall death rates while on the waiting list for the
entire lung transplant group was 134 per 1000 patient
years at risk in 2001, and represents a continual decline
over the decade. Patients aged 1–5 years showed an
almost threefold higher risk of death while waiting in
2001 (362 per 1000 patient years at risk) (Figure 9). In
children aged 6–10 years, risk of death while waiting
decreased from 231 in 1999 to 89 in 2001. The risk for
those aged 11–17 years (123) was slightly lower than the
overall group of all lung transplant registrants, but showed
a similar declining pattern over the 10 years studied. Thus,
the very youngest age groups appear to have an increased
risk of death while waiting, consistent with the limited
number of donors suitable for this population (due to size
considerations) and the severity of the illnesses for which
lung transplantation is considered. The primary indications
for lung transplants in young children include congenital
malformations of the lung, pulmonary hypertension, sur-
factant deficiencies, and other severe forms of pulmonary
fibrosis. Cystic fibrosis is a very infrequent indication for
transplant in this age range. The severity of the lung
diseases therefore may increase the risk of death while
waiting for organs from an increasingly rare donor pool.
Transplantation and survival
The number of pediatric lung transplants decreased
slightly to 46 in 2001. Out of the 1034 deceased donor
lung transplants performed in 2001, 28 were for pediatric
patients, representing only 3% of the total lung transplant
population.
Compared to adult recipients, lung graft survival is slightly
higher at 3 months for recipients aged 6–10 years (90%)
and 11–17 years (92%). Because of the small numbers of
patients receiving these grafts, however, the differences
in survival rates are not necessarily statistically significant.
Five-year graft survival rates in the pediatric population are
similar to those for the older patients, varying from 27% to
50%. The overall graft survival rate was 41% in the entire
lung transplant population.
Patient survival after lung transplantation in pediatric
patients appears to be similar to or slightly higher than in
the adult population at 5 years (Figure 10). The 5-year
survival rate for patients aged less than 1 year at transplant
was 33%; in those aged 6–10 years the survival rate was
64%. For recipients aged 11–17 years, 45% of patients
were alive at 5 years. Both these measurements have
large standard errors allowing for the possibility that over-
all survival rates are not different from the adult population
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Figure 9: Pediatric lung waitlist death rates per 1000 patient
years at risk by recipient age, 1992–2001. Source: 2002 OPTN/
SRTR Annual Report, Table 12.3.
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age less than 1 year appears to be associated with a
higher 5-year patient survival rate (54%) compared to
42% at 5 years in the overall group. This suggests that
the infant recipient of infant lungs may have an advantage,
as has been seen for cardiac transplantation in similar age
groups.
Lung transplantation in the pediatric population continued
to be an unusual procedure with graft and patient survival
rates similar to those seen in the adult populations. Very
young recipients may possess some shorter-term
immune advantage; however, the age cutoff at which
this and any improvement in longer-term outcome is
noted is still unclear, given the small number of patients
transplanted.
Overall, patient survival rates of 5 years are significantly
worse than for cardiac transplantation, again reflecting the
complexity of lung transplant immunology and the late




Pediatric registrants made up 17% of all heart–lung
waiting list patients in 2001. In contrast to the heart or
lung (alone) waiting lists, the absolute number of pediatric
registrants awaiting heart–lung transplantation remained
relatively constant and small over the past decade. In
2001, 25 new patients were registered across the entire
pediatric age range for this unusual procedure: age less
than 1 year (n¼ 7); ages 1–5 years (n¼ 4); ages 6–10 years
(n¼ 4); and ages 11–17 years (n¼ 10). These numbers are
somewhat decreased from the early 1990s. Deaths and
annual death rates per 1000 patient years at risk on the
waiting list for heart–lung transplants were significantly
increased in pediatric recipients compared with adults. In
2001, the overall waiting list death rate among all heart–
lung transplant candidates was 191 per 1000 patient years
at risk. For children aged 1–5 years, the risk was higher at
232. For those aged 11–17 years, risk was much higher
(468) compared with adults aged 18–34 years (159) and
with those aged 35–49 years (143). The reason for the wait-
ing list death rate among those aged 11–17 is not obvious.
However, it is possible that these children are in competi-
tion for organs with many older patients. The allocation
policy for heart–lung recipients may disadvantage children,
who are not suitable for assist devices for cardiac support,
resulting in a negative impact on overall waiting times and
the risk of death while waiting. Unfortunately, there are
insufficient data in any of the years to estimate the median
waiting time for pediatric heart–lung transplant recipients
and therefore this question cannot be directly addressed.
Transplantation and survival
Of the 27 heart–lung transplants performed in 2001, only
six were in children, again showing that heart–lung
transplantation is an extremely uncommon procedure in
pediatric patients and that the number of potential organs
is severely limited. Since 25 pediatric patients were added
to the waiting list in 2001 for heart–lung transplant and
only six received organs, it is likely that the limited avail-
ability of heart–lung blocks in the pediatric sizes accounted
for increased waiting list mortality in these age ranges.
Because of the infrequent number of transplants per-
formed in pediatric patients, there are no data available
regarding the annual death rates per 1000 patient years at
risk for recipients of heart–lung transplants in 2001.
Likewise, few meaningful data are available on graft sur-
vival at 3 months, 1 year, 3 years, and 5 years in pediatric
heart–lung transplant recipients because of the small num-
ber of transplants done. One exception is among recip-
ients aged 11–17 years. For these children, the 5-year
survival rate of 46% is similar to the survival rate of the
overall population. This suggests indirectly that there is no
graft survival disadvantage for pediatric subgroups. As
would be expected, patient survival largely mirrors graft
survival. Again, the only meaningful data available are for
recipients 11–17 year old, who have a 5-year survival rate
of 54%. This is slightly better than the overall survival for
the entire cohort (49%).
Heart–lung transplantation continues to be an extremely
rare procedure in the pediatric population. The limited
indications for heart–lung transplantation, the use of lung
transplantation for pulmonary diseases in preference to
heart–lung transplant in most centers, and the significant
limitation of donor organ availability have limited the use of
this procedure. Overall survival rates, however, after heart–
lung transplantation appear to be similar to those seen
























Figure 10: Patient survival among pediatric recipients of
deceased donor lung transplants, by recipient age. Source: 2002
OPTN/SRTR Annual Report, Table 12.9. Cohorts are for
transplants performed during 1999–2000 for 3-month and
1-year; 1997–1998 for 3-year; and 1995–1996 for 5-year survival.
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very limited number of transplants make statistically valid
comparisons difficult.
Conclusion
The number of pediatric registrants on the waiting list con-
tinued to increase, with the greatest stability seen in the
number of such patients awaiting heart and kidney trans-
plants. The greatest percentage increase was observed in
the number of pediatric registrants on the intestine and
lung waiting lists; the liver waiting list contained the largest
absolute number of pediatric registrants. And while the
number of pediatric donors remained steady over the last
10 years, the proportion of total donations represented by
these children declined to 16% in 2001, underscoring the
importance of increased awareness about the need for
pediatric organ donation. Infants and young children
undergoing living and deceased donor kidney transplanta-
tion now have the best long-term survival of all age
groups. Increasing numbers of children aged 11–17 years
received living donor liver grafts, with excellent patient
and graft survival ratesthough some less encouraging
trends also emerged during the study period. Several
advances in clinical practices and allocation policies
observed during the past decade offer hope for further
improvement of outcomes.
References
1. Dickinson DM, Ellison MD, Webb RL. Data sources and struc-
ture. Am J Transplant 2003; 3(Suppl. 4): 13–28.
2. Wolfe RA, Webb RL, Dickinson DM et al. Analytical approaches
for transplant research. Am J Transplant 2003; 3(Suppl. 4):
103–113.
3. US General Accounting Office. Organ Transplants: Allocation
Policies Include Special Protections for Children. Publication GAO-
01-498. Washington, DC: US General Accounting Office, 2001.
4. McEnery PT, Stablein DM, Arbus G, Tejani A. Renal transplant-
ation in children. A report of the North American Pediatric
Renal Transplant Cooperative Study. N Engl J Med, 1992; 326:
1727–1732.
5. Ettenger RB, Blifeld C, Prince H et al. The pediatric nephrolo-
gist’s dilemma: growth after renal transplantation and its inter-
action with age as a possible immunologic variable. J Pediatr
1987; 111: 1022–1025.
6. Seikaly M, Ho PL, Emmett L, Tejani A. The 12th Annual Report
of the North American Pediatric Renal Transplant Cooperative
Study: renal transplantation from 1987 through 1998. Pediatr
Transplant 2001; 5: 215–231.
7. Tejani A, Sullivan EK, Fine RN, Harmon W, Alexander S. Steady
improvement in renal allograft survival among North American
children: a five year appraisal by the North American Pediatric
Renal Transplant Cooperative Study. Kidney Int 1995; 48:
551–553.
8. Cecka JM, Gjertson DW, Terasaki PI. Pediatric renal transplant-
ation. A review of the UNOS data. Pediatr Transplant 1997; 1:
55–64.
9. Briscoe DM, Kim MS, Lillehei C, Eraklis AJ, Levey RH, Harmon
WE. Outcome of renal transplantation in children less than two
years of age. Kidney Int 1992; 42: 657–662.
10. Sarwal MM, Cecka JM, Millan MT, Salvatierra O Jr. Adult-size
kidneys without acute tubular necrosis provide exceedingly
superior long-term graft outcomes for infants and small children:
a single center and UNOS analysis. United Network for Organ
Sharing. Transplantation 2000; 70: 1728–1736.
11. Harmon WE, Alexander SR, Tejani A, Stablein D. The effect of
donor age on graft survival in pediatric cadaver renal transplant
recipients – a report of the North American Pediatric Renal Trans-
plant Cooperative Study. Transplantation 1992; 54: 232–237.
12. Harmon WE, Stablein D, Alexander SR, Tejani A. Graft throm-
bosis in pediatric renal transplant recipients. A report of the
North American Pediatric Renal Transplant Cooperative Study.
Transplantation 1991; 51: 406–412.
13. Wood EG, Hand M, Briscoe DM et al. Risk factors for mortality in
infants and young children on dialysis. Am J Kidney Dis 2001; 37:
573–579.
14. Warady BA, Sullivan EK, Alexander SR. Lessons from the peri-
toneal dialysis patient database. a report of the North American
Pediatric Renal Transplant Cooperative Study. Kidney Int 1996;
53 (Suppl ): S68–S71.
15. Singh A, Stablein D, Tejani A. Risk factors for vascular throm-
bosis in pediatric renal transplantation. a special report of the
North American Pediatric Renal Transplant Cooperative Study.
Transplantation 1997; 63: 1263–1267.
16. Baum MA, Stablein DM, Panzarino VM, Tejani A, Harmon WE,
Alexander SR. Loss of living donor renal allograft survival advan-
tage in children with focal segmental glomerulosclerosis. Kidney
Int 2001; 59: 328–333.
17. Delmonico FL, Harmon WE. The use of a minor as a live kidney
donor. Am J Transplant 2002; 2: 333–336.
18. Abecassis M, Adams M, Adams P et al. Consensus statement
on the live organ donor. JAMA 2000; 284: 2919–2926.
19. Broering DC, Mueller L, Ganschow R et al. Is there still a need
for living-related liver transplantation in children? Ann Surg 2001;
234: 713–721, discussion 721–722.
20. Farmer DG, Yersiz H, Ghobrial RM et al. Early graft function after
pediatric liver transplantation. comparison between in situ split
liver grafts and living-related liver grafts. Transplantation 2001;
72: 1795– 1802.
21. Wiesner RH, McDiarmid SV, Kamath PS et al. MELD and PELD.
application of survival models to liver allocation. Liver Transplan-
tation 2001; 7: 567–580.
22. Abu-Elmagd K, Reyes J, Bond G et al. Clinical intestinal trans-
plantation. A decade of experience at a single center. Ann Surg
2001; 234: 404–416, discussion 416–417.
23. Kaufman SS, Atkinson JB, Bianchi A et al. Indications for pedi-
atric intestinal transplantation. A position paper of the American
Society of Transplantation. Pediatr Transplant 2001; 5: 80–87.
24. West LI, Pollock-Barziv SM, Dipchand AI et al. ABO-incompatible
heart transplantation in infants. N Engl J Med 2001; 344: 793–800.
25. Liou TG, Adler FR, Cahill BC et al. Survival effect of lung trans-
plantation among patients with cystic fibrosis. JAMA 2001; 286:
2683–2689.
Pediatric transplantation
American Journal of Transplantation 2003; 3 (Suppl. 4): 53–63 63
